SynOx Therapeutics Ltd, an Irish incorporated clinical stage biopharmaceutical company, has announced the closing of a €37 million Series A financing co-led by HealthCap and Medicxi and joined by investors Forbion and Gimv.

SynOx, a spin out of oncology company Celleron Therapeutics Ltd, secured exclusive world-wide rights for the clinical development, manufacturing and commercialisation of targeted antibody drug emactuzumab under a licence agreement with Roche.

Philip Lee was delighted to provide Irish law advice to Celleron on the spin out of SynOx and the Series A financing.

Further details available here.